Chemotherapy-Induced Peripheral Neuropathy
Conditions
Interventions
Group A :TCM fumigation therapy plus Sensorimotor Training
Group B:TCM fumigation therapy
Group C:Mecobalamin Treatment
Sponsors
The First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with a histopathological diagnosis of cancer who are receiving chemotherapy regimens that may induce chemotherapy-induced peripheral neuropathy (CIPN), such as taxanes or platinum-based agents; (1)Patients who meet the above Western medicine diagnostic criteria as well as the Traditional Chinese Medicine (TCM) syndrome differentiation criteria for "Yang deficiency and cold coagulation"; 2. Age between 18 and 70 years; 3. No symptoms of CIPN (such as numbness, tingling, or hypoesthesia) prior to chemotherapy administration; 4. No severe systemic diseases, including: (1)Cardiovascular system: congestive heart failure (NYHA class III–IV), acute myocardial infarction, or uncontrolled hypertension (>180/110 mmHg); (2)Respiratory system: acute exacerbation of moderate-to-severe chronic obstructive pulmonary disease (COPD) or severe asthma; (3)Hepatic and renal function: severe hepatic failure (Child–Pugh class C) or renal failure (eGFR <30 mL/min); (4)Hematologic system: severe anemia (Hb <70 g/L) or platelet count <50×10^9/L; 5. Patients who voluntarily agree to participate in the study, sign the informed consent form, and are able to complete follow-up assessments as required.
Exclusion criteria
Exclusion criteria: 1. preexisting peripheral neuropathy due to other causes: neurological injury due to other neurological disorders (such as diabetic neuropathy, myelopathy, post-traumatic sequelae, etc.) ; 2. cognitive impairment or mental illness, inability to complete research interventions or assessments (EG, severe dementia, schizophrenia) ; 3. allergic to any of the pharmaceutical ingredients in the fumigated washing formula; 4. presence of skin infection, wound or other serious skin condition.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20-item scale( EORTC QLQ-CIPN20)); | — |
Secondary
| Measure | Time frame |
|---|---|
| European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core Scale(EORTC QLQ-C30); | — |
Countries
China
Contacts
Public ContactXiaonan Cui
The First Affiliated Hospital of Dalian Medical University
Outcome results
None listed